Margaret A. Tempero, MD

Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science, UCSF

Director, UCSF Pancreas Center; Leader, Pancreas Cancer Program; Professor of Medicine, Division of Hematology and Oncology, UCSF

Cancer Center Program Membership

Molecular Oncology

Research Summary

I am Director, UCSF Pancreas Center and Leader of the UCSF Pancreas Cancer Program. My research career has focused on pancreatic ductal adenocarcinoma, especially in the area of investigational therapeutics. I was a pioneer in the use of antibody-based therapies and helped develop the fixed dose rate concept for gemcitabine. My group has developed effective gemcitabine combinations and provided a foundation for using CA19-9 as a surrogate for survival in clinical trials, and currently is assessing molecular subtypes and molecular enrichment for selecting new drugs for clinical evaluation. I directed the first GI SPORE devoted to pancreatic cancer when I was on the faculty of the University of Nebraska and subsequently led the NCI-funded U54 Molecular Target Assessment Team at UCSF. I also organized the first Pancreas Cancer Think Tank in 1999 and co-led the NCI sponsored Progress Review Group on Pancreatic Cancer in 2000. I have served as the Chair of the NCCN Guidelines Panel on Pancreatic Cancer since 2000. I also serve as co-chair on the Pancreas Task Force Tissue Acquisition Working Group for the NCI intergroup and co-organized the State of the Science meeting on pancreatic cancer at the NCI.

I have extensive experience in scientific review and administration, training and oversight. I co-directed the AACR/ASCO Methods in Clinical Cancer Research in Vail for three years and spent nine years of service teaching this course and similar courses in Europe and Australia. I was founding Chair of the NCI Clinical Oncology Study Section (CONC) and served as a member and Chair (two-year term) of the NCI Board of Scientific Counselors Subcommittee A. I am on the External Advisory Boards of the Pancreas SPORE at the University of Alabama in Birmingham/University of Minnesota and the Mayo Clinic.

I am, or have been, on the Scientific Advisory Boards of the Lustgarten Foundation, the Pancreatic Cancer Action Network, the V Foundation, The Alberta Canada Cancer Board and the EORTC. I have held many appointments at AACR and ASCO and served as a member of the ASCO Board of Directors and as ASCO President in 2004. I served as a member of the Oncology Drug Advisory Committee for the FDA from 2007-2011. I served as Deputy Director and Interim Director for the UNMC Eppley Cancer Center until 1999, and Chief of the Division of Medical Oncology at UCSF (2000-2007) and Deputy Director and Director of Research Programs at the HDFCCC from 2000 to 2012.

Research Funding

  • July 1, 1984 - August 31, 2026 - Buffett Cancer Center Support Grant , Co-Principal Investigator . Sponsor: NIH, Sponsor Award ID: P30CA036727
  • August 5, 1999 - May 31, 2023 - Cancer Center Support Grant , Co-Investigator . Sponsor: NIH, Sponsor Award ID: P30CA082103
  • September 15, 2014 - August 31, 2018 - Perioperative Stromal Depletion Strategies in Pancreatic Ductal Adenocarcinoma , Principal Investigator . Sponsor: NIH, Sponsor Award ID: R21CA184429
  • September 26, 2001 - December 31, 2008 - Mechanism-Based Evaluations of ErbB-Targeted Agents , Principal Investigator . Sponsor: NIH, Sponsor Award ID: U54CA090788

Education

Creighton University, Omaha, NE, B.S., 1969, Medical Technology
University of Nebraska Medical Center, Omaha, NE, M.S., 1974, Clinical Pathology
University of Nebraska Medical Center, Omaha, NE, M.D., 1977, Medicine
University of Nebraska Medical Center, Omaha, NE, Residency, 1980, Internal Medicine
University of Nebraska Medical Center, Omaha, NE, Fellowship, 1983, Oncology

Honors & Awards

  • Editor-In-Chief, Journal Nat'l Comprehensive Cancer Network, 2014-Pres
  • Rombauer Family Distinguished Professorship in Pancreas Cancer Clinical and Translational Science, UCSF, 2012-Pres
  • Doris and Don Fisher Distinguished Professor in Clinical Research, UCSF, 2000-2012

Selected Publications

  1. Tempero M. Failure Doesn't Feel Good! J Natl Compr Canc Netw. 2022 07; 20(7):737.  View on PubMed
  2. Tempero M. I Cannot Afford This! J Natl Compr Canc Netw. 2022 06; 20(6):615.  View on PubMed
  3. Tempero M. Out in the World Again. J Natl Compr Canc Netw. 2022 05; 20(5):429.  View on PubMed
  4. Tempero M. It's OK to Share! J Natl Compr Canc Netw. 2022 04; 20(4):317.  View on PubMed
  5. Walker EJ, Blanco AM, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH. The Additional Diagnostic Benefit of Pancreatic Cancer Molecular Profiling After Germline Testing. Pancreas. 2022 04 01; 51(4):302-304.  View on PubMed
  6. Tempero M. Getting Complex Therapies to More People: A Vexing Dilemma. J Natl Compr Canc Netw. 2022 03; 20(3):217.  View on PubMed
  7. Tempero M. News About the Tiny Pharmacists Within Us. J Natl Compr Canc Netw. 2022 02; 20(2):99.  View on PubMed
  8. Burns S, Vella M, Paciorek A, Zhang L, Atreya CE, Feng M, Kelley RK, Tempero MA, Van Loon K, Ko AH. Characteristics and Growth Rate of Lung Metastases in Patients With Primary Gastrointestinal Malignancies and Lung-dominant Metastatic Disease: A Retrospective Cohort Analysis. Am J Clin Oncol. 2022 01 01; 45(1):22-27.  View on PubMed
  9. Tempero M. Starting Over, Again! J Natl Compr Canc Netw. 2022 01; 20(1):1.  View on PubMed
  10. Tempero M. Thank You, Santa! J Natl Compr Canc Netw. 2021 12; 19(12):1365.  View on PubMed
  11. Sessa C, Cortes J, Conte P, Cardoso F, Choueiri T, Dummer R, Lorusso P, Ottmann O, Ryll B, Mok T, Tempero M, Comis S, Oliva C, Peters S, Tabernero J. The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspective. ESMO Open. 2022 02; 7(1):100339.  View on PubMed
  12. Tempero M. Reimagining Professional Meetings: Another Lesson From COVID-19. J Natl Compr Canc Netw. 2021 11; 19(11):1211.  View on PubMed
  13. Tempero M. Five Patients and One Important Lesson. J Natl Compr Canc Netw. 2021 10 15; 19(10):1115.  View on PubMed
  14. Walker EJ, Goldberg D, Gordon KM, Pedley C, Carnevale J, Cinar P, Collisson EA, Tempero MA, Ko AH, Blanco AM, Dhawan M. Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma. Oncologist. 2021 11; 26(11):e1982-e1991.  View on PubMed
  15. Tempero M. Targeting KRAS: Good, But Is It Good Enough? J Natl Compr Canc Netw. 2021 09 20; 19(9):997.  View on PubMed
  16. Rustgi AK, Hines OJ, Tempero MA, Saluja AK, Habtezion A, Li M, Uc A, Go VLW. Minutes of the Business Meeting of the American Pancreatic Association, Sunday, November 1, 2020, Virtual Meeting. Pancreas. 2021 08 01; 50(7):1042-1043.  View on PubMed
  17. Tempero M. Something to Crow About! J Natl Compr Canc Netw. 2021 08 01; 19(8):881-882.  View on PubMed
  18. Tempero M. Pan-Cancer Screening: A Dream or a Nightmare. J Natl Compr Canc Netw. 2021 07 28; 19(7):773.  View on PubMed
  19. Von Hoff DD, Clark GM, Coltman CA, Disis ML, Eckhardt SG, Ellis LM, Foti M, Garrett-Mayer E, Gönen M, Hidalgo M, Hilsenbeck SG, Littlefield JH, LoRusso PM, Lyerly HK, Meropol NJ, Patel JD, Piantadosi S, Post DA, Regan MM, Shyr Y, Tempero MA, Tepper JE, Von Roenn J, Weiner LM, Young DC, Vu NV. A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. Clin Cancer Res. 2021 10 15; 27(20):5472-5481.  View on PubMed
  20. Tempero M. Informed Consent: Is It Really? J Natl Compr Canc Netw. 2021 06 30; 19(6):665.  View on PubMed

Go to UCSF Profiles, powered by CTSI